コンテンツにスキップ
25% off all books & eBooks25% off all books & eBooks

Non-Alcoholic Fatty Liver Disease, An Issue of Clinics in Liver Disease, 1st Edition

著者 :
By Paul J. Gaglio, MD, FACP, AGAF, FAASLD
Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can prog ...view more
Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.
ISBNコード :
9780323416962
出版日 :
15-04-2016
カートに入れる

!洋書籍は不課税のため消費税不適用、電子書籍は消費税がご注文決済前に表示・適用されます!

!洋書籍は不課税のため消費税不適用、電子書籍は消費税がご注文決済前に表示・適用されます!

Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.

著者情報
By Paul J. Gaglio, MD, FACP, AGAF, FAASLD, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY